Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. by Diéras, Véronique et al.
UCSF
UC San Francisco Previously Published Works
Title
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy 
for HR+/HER2- Advanced Breast Cancer.
Permalink
https://escholarship.org/uc/item/2f01f5cf
Journal
Journal of the National Cancer Institute, 111(4)
ISSN
0027-8874
Authors
Diéras, Véronique
Rugo, Hope S
Schnell, Patrick
et al.
Publication Date
2019-04-01
DOI
10.1093/jnci/djy109
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ARTICLE
Long-term Pooled Safety Analysis of Palbociclib
in CombinationWith Endocrine Therapy for
HR1/HER2- Advanced Breast Cancer
Veronique Dieras, Hope S. Rugo, Patrick Schnell, Karen Gelmon, Massimo Cristofanilli,
Sherene Loi, Marco Colleoni, Dongrui R. Lu, Ave Mori, Eric Gauthier, Cynthia
Huang Bartlett, Dennis J. Slamon, Nicholas C. Turner, Richard S. Finn
See the Notes section for the full list of authors’ affiliations.
Correspondence to: Veronique Dieras, MD, Centre Euge`ne Marquis, Avenue de la Bataille, Flandres-Dunkerque, CS 44229, 35042 RENNES CEDEX, France
(e-mail: v.dieras@rennes.unicancer.fr).
Abstract
Background: Palbociclib administered with endocrine therapy was tolerable when the overall incidence of toxicities was
assessed separately for three PALOMA studies. This study analyzed pooled, longer-term PALOMA safety data longitudinally.
Methods: Data were pooled from three randomized phase II and III studies (ClinicalTrials.gov: NCT00721409, NCT01740427,
NCT01942135) of hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer
patients. Front-line patients were randomly assigned to receive letrozole with/without palbociclib (PALOMA-1) or letrozole
plus palbociclib/placebo (PALOMA-2). In PALOMA-3, patients with prior endocrine resistance received fulvestrant plus palbo-
ciclib/placebo. The cumulative event rates of adverse events (AEs), reporting up to 50 months of treatment, were assessed
over time.
Results: Patients who received endocrine therapy (n ¼ 1343) were included in this pooled analysis (872 were also treated with
palbociclib, and 471 were not). The most common AEs with palbociclib plus endocrine therapy were neutropenia and
infections (any grade, 80.6% and 54.7%, respectively), which were higher than in the endocrine monotherapy arm (any grade,
5.3% and 36.9%). The most common hematologic AEs (15.0% in the palbociclib arm) were more likely to be reported in the
initial months of the study, after which time the cumulative event rate did not substantially increase. With palbociclib plus
endocrine therapy, any grade AEs leading to permanent discontinuation over three years occurred in only 8.3% of patients.
Conclusions: Based on these long-term safety analyses, there is no evidence of specific cumulative or delayed toxicities with
palbociclib plus endocrine therapy, supporting the ongoing investigation of palbociclib plus endocrine therapy in early breast
cancer (NCT02513394).
The novel and selective cyclin-dependent kinase 4 and 6 (CDK4/
6) inhibitor palbociclib, used in combination with endocrine
therapy, has demonstrated efficacy and tolerable safety in
the management of metastatic or locally advanced breast cancer
(1–4). Palbociclib targets dysregulated cell cycle machinery within
the cyclin D-CDK4/6-retinoblastoma pathway to inhibit the
uncontrolled cellular proliferation critical to pathophysiologic
processes (5–7). In prospective, randomized phase II and III trials,
palbociclib combined with endocrine therapy resulted in statisti-
cally significant (P < .001) improvement in progression-free
survival (PFS) compared with endocrine therapy alone, in both
firstline metastatic and previously treated hormone receptor
positive/human epidermal growth factor receptor 2negative
(HRþ/HER2-) patients with advanced breast cancer (1–4).
A
R
T
IC
LE
Received: August 23, 2017; Revised: April 10, 2018; Accepted: May 22, 2018
© The Author(s) 2018. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work
is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contactjournals.permissions@oup.com
419
JNCI J Natl Cancer Inst (2019) 111(4): djy109
doi: 10.1093/jnci/djy109
First published online July 18, 2018
Article
The therapeutic window of any new treatment regimen
needs to be evaluated for efficacy vs the clinically tolerable
safety profile, particularly in the advanced disease setting,
where maintaining quality of life and minimizing toxicity are a
priority. Decisions on treatment with CDK4/6 inhibitors, includ-
ing palbociclib in combination regimens, need to be based on an
assessment of their immediate and long-term toxicity. The
safety profile of palbociclib plus endocrine therapy has been
reported for each of the three PALOMA studies at both interim
and final analysis of the primary end point (investigator-
assessed PFS) (1–3). Further analysis of the safety profile to char-
acterize the incidence of adverse events (AEs) over time will
enhance the ability of clinicians to manage toxicities, optimize
treatment decisions, and appropriately counsel their patients
(8). In this analysis, we evaluate the safety of palbociclib com-
bined with endocrine therapy for up to 50 months—which
extends beyond the cutoff dates of the safety data reported pre-
viously for PALOMA-1, -2, and -3—to characterize toxicities and
identify any unusual trends and/or potential cumulative AEs
based on a longitudinal analysis of a large, pooled clinical trial
data set comprising all three randomized studies.
Methods
Study Design and Patients
This analysis includes safety data from the open-label, phase II
PALOMA-1 study and the double-blind, phase III PALOMA-2 and
-3 studies (ClinicalTrials.gov: NCT00721409 [9], NCT01740427
[10], NCT01942135 [11], respectively). All three PALOMA study
designs, briefly shown in Supplementary Figure 1 (available on-
line), have been described previously (1–4). Across all PALOMA
studies, written informed consent was provided before study
procedures were initiated; institutional review boards at partici-
pating centers approved all study-related procedures, which
complied with the International Conference on Harmonisation,
guidelines for Good Clinical Practice, and the Declaration of
Helsinki. Overall survival has been reported for PALOMA-1 (12),
and follow-up is in progress for the PALOMA-2 and PALOMA-3
studies.
Eligible patients were postmenopausal women (PALOMA-1
and -2) and women of any menopausal status (PALOMA-3) age
18 years or older with HRþ/HER2- advanced breast cancer who
had not received treatment for their advanced breast cancer
(PALOMA-1 and -2), or whose advanced breast cancer had pro-
gressed on prior endocrine therapy while on or within 12
months of (neo)adjuvant therapy (including some endocrine
therapies), or while on or within one month of endocrine ther-
apy for advanced breast cancer (PALOMA-3). Other key inclusion
criteria appear in Supplementary Table 1 (available online).
Study treatments have been previously described (1–3) and are
summarized in the Supplementary Methods (available online).
Safety Assessments
AEs in all three PALOMA studies were reported from the time
patients provided informed consent until at least 28 days after
their last study drug treatment and before the initiation of any
new anticancer therapy, or until all toxicities resolved or were
characterized as chronic/stable in PALOMA-1, whichever oc-
curred later. AEs were assessed at least monthly; laboratory
tests were performed biweekly during the first two cycles and
on day 1 of subsequent cycles; blood counts were performed on
day 15 6 1 day for the first two cycles, on day 1 of subsequent
cycles, and at the end of treatment or withdrawal; physical
examinations were performed at screening and on day 1 of ev-
ery cycle until the end of treatment or withdrawal.
The severity of all-causality AEs was recorded by investiga-
tors and graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events (CTCAE) v3.0
(PALOMA-1) and v4.0 (PALOMA-2 and -3). Serious AEs were also
assessed.
Data and Statistical Analyses
AEs were coded using the Medical Dictionary for Regulatory
Activities (MedDRA) v19.0. The frequencies of maximum grade
events for each patient during study treatments were sum-
marized by treatment arms. Related preferred terms were
aggregated into cluster terms (Supplementary Methods,
available online). To evaluate the long-term safety of palbo-
ciclib combined with endocrine therapy, the cumulative
event rates of hematologic and selected nonhematologic
AEs—recognized as being of clinical relevance—were
assessed using Kaplan-Meier estimates. Frequently reported
AEs, in 15% or more of palbociclib-treated patients, were
assessed at six-month intervals (0–<6, 6–<12, 12–<18, 18–<24,
24–<30, 30–<36 months).
To assess the risk of having an AE in palbociclib-treated
patients (compared with patients receiving endocrine mono-
therapy), hazard ratios for each AE of interest were estimated
using a Cox model stratified by study. A log-rank test was used
to derive P values (two-sided) without adjustment for multiplic-
ity. P values of less than .05 were considered statistically signifi-
cant. In addition, person-years analysis was conducted for
selected nonhematologic AEs to adjust the duration of drug ex-
posure to the risk of having the AE. For venous thromboembolic
events, treatment duration–adjusted incidence rates per person
per year were based on the Standardised MedDRA Query v20.0
for venous embolic and thrombotic events.
Mean CTCAE grades for selected hematologic (laboratory-
assessed) and nonhematologic adverse events were calculated
by cycle for the first 18 cycles of treatment. The frequency of
AEs leading to temporary dose discontinuations (dose interrup-
tions within a cycle or a delay of the next treatment cycle) over
six-month intervals and cumulatively was also summarized.
Results
Patients
The experimental arm of this pooled data set includes 875
patients randomly assigned to the palbociclib arms in the three
PALOMA studies (intent-to-treat population: PALOMA-1, n ¼ 84,
data cutoff date, January 2, 2015; PALOMA-2, n ¼ 444, February
26, 2016; PALOMA-3, n ¼ 347, July 31, 2015). Pooled analyses ex-
cluded one patient in PALOMA-1 and two patients in PALOMA-3
who were randomly assigned to palbociclib but not treated
(safety population: n ¼ 872). The comparator arm includes 477
patients randomly assigned to endocrine monotherapy or endo-
crine therapy 6 placebo. Four patients in PALOMA-1 and 2
patients in PALOMA-3 were randomized but did not receive ther-
apy (safety population: n ¼ 471). The mean age of the pooled
intent-to-treat population was similar in the palbociclib plus en-
docrine arm and endocrine monotherapy arm, and most patients
were postmenopausal (Table 1).
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Exposure
Median duration of treatment was longer (all three studies), and
median relative dose intensities slightly lower (for PALOMA-2
and PALOMA-3 studies), in the palbociclib-treated arms than
the corresponding endocrine monotherapy arms (Table 2). In
119 of 527 (22.6%) patients in PALOMA-1 and -2, the combination
of palbociclib and letrozole as firstline treatment was continued
for 24 to less than 30 months, and 11 patients were treated for
more than 36 months. For 140 of 345 (40.5%) patients in
PALOMA-3, palbociclib plus fulvestrant was received for 12 or
more months. Dose reductions were required in 36.9% of the
pooled safety population that received palbociclib plus endo-
crine therapy (Table 2). Median durations of exposure to endo-
crine therapy in the comparator arms were consistently less
than for the palbociclib arm, irrespective of the line of therapy.
The total duration of treatment was 2.4-fold longer in the palbo-
ciclib arm than the comparator arm (Table 2).
AE Incidence
A summary table of any grade treatment-emergent adverse
events reported in 15.0% or more of patients in either treatment
arm of this pooled study is shown in Table 3. Grade 34 hema-
tologic toxicities were reported for 98.6% of patients in the
palbociclib-treated arm and for 3.6% of patients in the endocrine
monotherapy arm. Any grade neutropenia, the most common
hematologic AE in the palbociclib-treated arm, was reported for
80.6% and 5.3% patients in the palbociclib-treated and endo-
crine monotherapy arms, respectively.
Any grade infections, the most common nonhematologic
AEs in the palbociclib-treated and endocrine monotherapy
arms, were reported for 54.7% and 36.9% patients, respectively,
and in 431 of 477 (90.4%) and 159 of 174 (91.4%) of those patients,
events were of grade 12 severity. There were no grade 5 infec-
tions reported for palbociclib-treated patients, whereas three
events of grade 5 severity (pneumonia, lower respiratory tract
infection, and peritonitis bacterial) were reported for patients
receiving endocrine monotherapy (Table 3). The five most com-
mon any grade infections with palbociclib plus endocrine ther-
apy were nasopharyngitis (13.6% and 9.1% with endocrine
monotherapy), upper respiratory tract infection (11.7% and
8.3%, respectively), urinary tract infection (10.0% and 6.8%), and
oral herpes (4.2% vs 0.8%) (data not shown).
Fatigue and nausea were among the other most common
nonhematologic toxicities in both treatment arms; these events
were predominantly of grade 12 severity.
Timing and Cumulative Event Rates of AEs
The cumulative event rates of the four most common all-
causality hematologic AEs over all cycles for up to 50 months
are depicted for the 872 patients treated with palbociclib plus
endocrine therapy in Figure 1A. Kaplan-Meier plots show that
the probability of any grade neutropenia being reported was
greater than 0.6 within the first two months of treatment, after
which time the increase of the cumulative event rate was mini-
mal and relatively gradual (>0.8 by month 10 and <0.9 over the
next 40 months). The cumulative event rate of any grade leuko-
penia being reported was greater than 0.3 within the initial
months of the study, it reached greater than 0.4 by month 10,
and thereafter it increased to approximately 0.5 and plateaued.
The probability of any grade anemia and thrombocytopenia
being reported was greater than 0.1 within the initial three
months of treatment, after which time it reached greater
than 0.3 for reports of anemia and greater than 0.2 for thrombo-
cytopenia by month 20; the cumulative event rate for re-
porting anemia and thrombocytopenia reached a plateau of
approximately 0.4 and less than 0.3, respectively, by approxi-
mately month 30.
Among the selected nonhematologic AEs of any grade
(Figure 1B), the cumulative event rates for fatigue, nausea, infec-
tions, and stomatitis were greater than 0.2 within the initial few
months of palbociclib plus endocrine therapy. The cumulative
Table 1. Patient demographic and baseline clinical characteristics
(intent-to-treat population)
Characteristic
Palbociclib þ
endocrine
therapy
(n ¼ 875)
Endocrine
therapy*
(n ¼ 477)
Age, y
Mean (range) 60 (30–89) 60 (28–88)
<65, No. (%) 571 (65.3) 314 (65.8)
65, No. (%) 304 (34.7) 163 (34.2)
75, No. (%) 83 (9.5) 32 (6.7)
Race, No. (%)
White 672 (76.8) 377 (79.0)
Asian 145 (16.6) 65 (13.6)
Black 21 (2.4) 12 (2.5)
Other† 37 (4.2) 23 (4.8)
Menopausal status, No. (%)
Pre-/perimenopausal 72 (8.2) 36 (7.5)
Postmenopausal 803 (91.8) 441 (92.5)
ECOG PS, No. (%)
0 509 (58.2) 263 (55.1)
1 357 (40.8) 211 (44.2)
2 9 (1.0) 3 (<1.0)
Disease sites, No. (%)
Visceral 452 (51.7) 257 (53.9)
Nonvisceral 423 (48.3) 220 (46.1)
No. of disease sites†, No. (%)
1 272 (31.1) 144 (30.2)
2 231 (26.4) 118 (24.7)
3 203 (23.2) 114 (23.9)
4 106 (12.1) 63 (13.2)
5 63 (7.2) 38 (8.0)
Measurable disease, No. (%)
Yes 671 (76.7) 375 (78.6)
No 204 (23.3) 102 (21.4)
Disease stage at initial diagnosis, No. (%)
I 77 (8.8) 43 (9.0)
II 257 (29.4) 124 (26.0)
III 141 (16.1) 86 (18.0)
IV 224 (25.6) 108 (22.6)
Other 21 (2.4) 9 (1.9)
Unknown/missing 71 (8.1) 26 (5.5)
Not collected 84 (9.6) 81 (17.0)
Prior systemic therapy, No. (%)
Hormonal 623 (71.2) 328 (68.8)
Chemotherapy 495 (56.6) 283 (59.3)
None 211 (24.1) 118 (24.7)
*Comparator arm received endocrine therapy 6 placebo. ABC ¼ advanced breast
cancer (includes metastatic breast cancer); ECOG ¼ Eastern Cooperative
Oncology Group; PS ¼ performance status.
†Includes patients with missing/unreported information.
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event rate of reporting infections surpassed those for all other
AEs before five months (Figure 1B), increasing to approximately
0.6 by 15 months, and increasing more slowly to greater than
0.8 by 35 months. By comparison, the cumulative event rates for
reports of all other nonhematologic AEs were less than 0.5 by 30
months of palbociclib treatment, most of which had plateaued
by that time.
To evaluate the risk of an AE in palbociclib-treated patients
compared with patients receiving endocrine monotherapy, a
forest plot of hazard ratios for a group of selected clinically rele-
vant AEs is presented in Figure 2. Although all selected AEs in
the forest plot show that there is an increased risk in the
palbociclib-treated arm compared with the control arm, the he-
matologic AEs are statistically significantly higher in the
palbociclib-treated arm (all P < .001).
Adverse Events Adjusted for Exposure
The incidence rate of selected AEs was assessed in each of the
treatment arms after adjusting for the duration of exposure to
treatment (Figure 3). Between treatment arms, the incidence
rate of stomatitis was higher in palbociclib-treated patients af-
ter controlling for the duration of exposure to study drugs;
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Figure 1. Kaplan-Meier curves showing cumulative event rates over time among palbociclib-treated patients for the (A) hematologic adverse events (AEs) of neutrope-
nia, leukopenia, anemia, and thrombocytopenia and for (B) selected nonhematologic AEs. *Cluster terms were used and are defined in the Supplementary Methods
(available online).
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however, differences between treatment arms for febrile neutro-
penia, infections, fatigue, and nausea, among other AEs, were
mitigated to some extent after controlling for duration of treat-
ment. The rate of pulmonary embolism was the same in both
arms after adjusting for duration of exposure to treatment (0.017
person-years in both arms), and the rate for all venous thrombo-
embolic events was 0.025 person-years in the palbociclib-treated
arm vs 0.027 in the endocrine monotherapy arm.
Adverse Events and Dose Modifications Over Time
Treatment-emergent AEs were assessed at six-month intervals
for less than 36 months. The incidence of any grade AEs
reported for 15.0% or more of patients had a similar trend over
time; all toxicities peaked during the first six months of treat-
ment (Supplementary Figure 2, available online) and generally
decreased over time, with the greatest decrease occurring after
the first six months of treatment. With the exception of neutro-
penia, leukopenia, and infections, the incidence of individual
AEs remained below 15.0% at each time interval after the first
six months.
The rate of dose modifications associated with AEs showed
a similar temporal pattern, with dose reductions and temporary
discontinuations (dose interruptions and cycle delays) most
commonly implemented during the first six months of treat-
ment with palbociclib plus endocrine therapy (Table 4). The fre-
quency of dose reductions and temporary discontinuations
decreased over time. Any grade AEs leading to a dose reduction
and/or a temporary discontinuation over three years were 36.0%
and 71.4%, respectively. The maximum number of dose reduc-
tions and dose interruptions were initiated in cycles 2 and 1, re-
spectively, and the frequency of each generally declined over
the course of subsequent treatment cycles, reaching 0% in later
cycles (Figure 4). Overall, neutropenia and leukopenia were the
most common AEs associated with dose reductions (29.8% and
3.1%, respectively) and temporary discontinuations (62.5% and
12.6%); however, few patients (1.5% and 0%) permanently dis-
continued treatment because of neutropenia and leukopenia.
Serious AEs, Permanent Discontinuations, and Grade 5
Events
All causalities, all cycles, any grade treatment-emergent serious
AEs (SAEs) were reported in a total of 160 of 872 (18.3%) patients
treated with palbociclib and in 65 of 471 (13.8%) patients receiv-
ing endocrine monotherapy (data not shown). The most com-
mon SAEs in palbociclib-treated patients were pulmonary
embolism, reported in 11 (1.3%) patients, and febrile neutrope-
nia, reported in nine (1.0%); no other SAEs occurred in more
than 1.0% of patients, including patients receiving endocrine
monotherapy (comparator arm: pulmonary embolism, three
[0.6%] patients; febrile neutropenia, one [0.2%] patient). The
overall permanent discontinuation rate due to any grade AEs in
those receiving palbociclib was 8.3% (72/872 patients) over three
years, and 91.4% remained on palbociclib regardless of treat-
ment combination. No treatment-related deaths occurred dur-
ing the trial or the 28 days after the last dose of study drug
among patients receiving palbociclib in the three pooled
PALOMA studies. During the safety period evaluated, grade 5
events occurred in 15 of 872 (1.7%) patients receiving palbociclib
plus endocrine therapy and in seven of 471 (1.5%) in the endo-
crine therapy comparator arm.
Adverse Events of Interest
The average burden of AEs for patients receiving palbociclib
plus endocrine therapy over the initial 18 treatment cycles was
consistently low for infections, nausea, and fatigue, with the av-
erage CTCAE grade of these events remaining below 2
(Supplementary Figure 3, available online). Among patients who
experienced grade 34 neutropenia (laboratory-based findings),
the mean CTCAE grade of these events decreased slightly after
the second cycle, from 3.1 in cycle 1 to 3.0 by cycle 3, and then
remained within this narrow range through cycle 18. The mean
CTCAE grade for neutropenia remained stable over time with
the implementation of dose modifications during the same
period.
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Figure 2. Forest plot depicting the estimated hazard ratios and 95% confidence intervals (CIs) in descending order for hematologic and selected nonhematologic ad-
verse events (AEs; all causalities, all cycles) in the as-treated population. A log-rank test was used to derive P values (two-sided) without adjustment for multiplicity.
*Cluster terms were used and are defined in the Supplementary Methods (available online). †Includes data up to 28 days after last dose of study drug, and the time to
an event in days was calculated as the date of AE onset minus the date of the first dose of palbociclib/placebo þ 1. Endocrine therapy included placebo in PALOMA-2
and -3, but not in the PALOMA-1 study.
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The incidence of any grade febrile neutropenia in
palbociclib-treated patients during the first 18 months of treat-
ment was low (0<6 months, 11/872 [1.3%]; 6<12 months,
2/676 [0.3%], and 12<18 months, 1/491 [0.2%]); there were no
subsequent events, and the reported incidence over the entire
study period was 14 (1.6%) for febrile neutropenia of any grade
(data not shown).
Hepatic Function
Pooled incidences of any grade (grades 14) laboratory eleva-
tions in the palbociclib-treated and comparator arms were as
follows: alanine aminotransferase (ALT) 40.8% and 31.1%, re-
spectively; aspartate aminotransferase (AST) 48.4% and 40.8%;
alkaline phosphatase 36.1% and 43.7%; and total bilirubin 7.9%
and 6.0% (data not shown). Overall, the rate of grade 34 he-
patic toxicities was low, although grade 3–4 laboratory values
were more frequently observed in the palbociclib-treated
patients than in the comparator arm for ALT, 2.3% and 0.2%,
and AST, 3.3% and 1.9%, respectively. No cases meeting the cri-
teria for Hy’s Law (13) were observed in palbociclib-treated
patients.
Growth Factors
Granulocyte colony-stimulating factors (G-CSFs) usage peaked
during cycles 1 and 8 (40 of 872 [4.6%] and 35 of 658 [4.6%]
patients, respectively); thereafter, the percentage of patients re-
ceiving G-CSFs gradually declined over subsequent cycles and
reached no G-CSF use at all by cycle 30 until cycle 58 (Figure 4C).
Discussion
Based on pooled data from the 3 PALOMA studies, the current
report represents the largest and most comprehensive analysis
of the long-term safety of palbociclib combined with endocrine
therapy in patients with HRþ disease, the most common breast
cancer subtype. The safety profile of palbociclib plus endocrine
therapy in this pooled analysis remains consistent with previ-
ously reported results for palbociclib plus letrozole in patients
who were front-line metastatic (PALOMA-1 and -2) and for
those who received palbociclib plus fulvestrant to treat disease
that progressed on prior endocrine therapy in the advanced
breast cancer setting (PALOMA-3) (1–3). With regard to QTc
prolongation, which has been shown to be a concern with
certain CDK4/6 inhibitors, even in patients not considered to
be at high risk for such an event (14), the recent results for cor-
rected QT (QTc) evaluations in PALOMA-2 patients indicated
that palbociclib plus letrozole does not prolong QTc to a clini-
cally relevant extent at the recommended 125 mg/d dosing
regimen (15).
Hematologic AEs, particularly cytopenias, are among the
most commonly observed toxicities with palbociclib treatment.
Although neutropenia is the most frequently reported AE of any
grade, relatively few patients experienced febrile neutropenia,
and the rate of permanent treatment discontinuation associ-
ated with neutropenia was low. Among patients who experi-
enced grade 34 neutropenia, the average severity grade of
neutropenia remained relatively stable and at the low end of
the grade 34 range over time, indicating a lack of cumula-
tive myelotoxicity with prolonged palbociclib treatment.
Additionally, the average severity of neutropenia in this
study decreased slightly after the second cycle, possibly be-
cause of dose modifications triggered by grade 4 neutropenia
events that tend to occur early during treatment.
Previous reports showed that one or more dose modifica-
tions (dose reduction, dose interruption, or cycle delay) for the
management of neutropenia or any AE did not significantly al-
ter the treatment effect of palbociclib plus endocrine therapy
on PFS (16–19). These observations are consistent with the pro-
posed noncytotoxic mechanism of palbociclib-induced bone
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Figure 3. Adverse event (AE) incidence rate of selected nonhematologic AEs in the safety population after adjusting by person-years of exposure to study drugs.
*Cluster terms were used and are defined in the Supplementary Methods (available online). †Incidence rate for selected AEs (preferred term/cluster of preferred
terms) ¼ (sum of total number of events)/(sum of total person-years).
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marrow suppression and are unlike the effects of chemother-
apy (20).
The incidence of hematologic and nonhematologic AEs
peaked within the first six months of palbociclib plus endocrine
therapy, temporally coinciding with the period of most dose
modifications (cycles 1 and 2). Early recognition of AEs is crucial
for their successful management because it allows continued
treatment and optimization of treatment outcomes. AEs associ-
ated with palbociclib plus endocrine therapy, including the
most common toxicities (ie, neutropenia, infections, leukope-
nia, fatigue, nausea), generally tapered off over time. The major-
ity of patients (63%) did not require a dose reduction and
remained on the full 125 mg/d dose during treatment. The cu-
mulative incidence of AEs during up to 50 months of treatment
was very similar over time, and the rate of permanent discon-
tinuation associated with AEs remained low, indicating that
these toxicities were well managed. The most frequently used
toxicity management techniques were dose reductions and
temporary discontinuations. Although cytopenias (particularly
neutropenia and leukopenia) were the most common reason for
dose modifications, clinical management of other AEs was
achieved effectively using these methods, and only four nonhe-
matologic AEs (fatigue, increased alanine aminotransferase,
infections, and disease progression) were associated with per-
manent treatment discontinuation in more than two patients.
Relevant resources that provide recommendations on the man-
agement of dose modifications in response to toxicities are
available to treating physicians (21,22).
At present there are no definitive predictive markers for
short- or long-term toxicity to indicate which patients may bet-
ter tolerate and benefit more from the addition of a CDK4/6 in-
hibitor to endocrine treatment. However, it has been reported
on the basis of a univariate analysis of PALOMA-2 study data
that Asian ethnicity and a baseline absolute neutrophil count
lower than 3.68103/mm3 represent potential risk factors for
the development of grade 3–4 neutropenia (17). Further research
on this topic is warranted given that it is information that can
facilitate the conservation of health care resources in cases
when endocrine monotherapy may suffice. Such insights could
also reduce the likelihood of toxicity in potentially at-risk
patients in both the adjuvant and advanced disease settings to
minimize the impact on day-to-day quality of life (QoL). It is
Table 4. Dose reductions and discontinuations associated with AEs over time
Time interval, mo
Dose reductions and
discontinuations
0 to <6
(n ¼ 872),
No. (%)
6 to <12
(n ¼ 676),
No. (%)
12 to <18
(n ¼ 491),
No. (%)
18 to <24
(n ¼ 289),
No. (%)
24 to <30
(n ¼ 119),
No. (%)
30 to <36
(n ¼ 27),
No. (%)
Dose reductions*
Any AE 243 (27.9) 69 (10.2) 33 (6.7) 18 (6.2) 3 (2.5) 0
Neutropenia† 210 (24.1) 49 (7.2) 24 (4.9) 16 (5.5) 3 (2.5) 0
Leukopenia† 25 (2.9) 3 (0.4) 1 (0.2) 0 0 0
Thrombocytopenia† 8 (0.9) 1 (0.1) 0 1 (0.3) 0 0
Infections† 4 (0.5) 4 (0.6) 2 (0.4) 1 (0.3) 0 0
Temporary discontinuations‡
Any AE 539 (61.8) 326 (48.2) 198 (40.3) 118 (40.8) 41 (34.5) 8 (29.6)
Neutropenia† 480 (55.0) 271 (40.1) 174 (35.4) 107 (37.0) 35 (29.4) 6 (22.2)
Leukopenia† 89 (10.2) 23 (3.4) 12 (2.4) 8 (2.8) 2 (1.7) 0
Infections† 24 (2.8) 31 (4.6) 22 (4.5) 6 (2.1) 3 (2.5) 0
Fatigue 12 (1.4) 6 (0.9) 8 (1.6) 2 (0.7) 1 (0.8) 0
Thrombocytopenia† 13 (1.5) 4 (0.6) 3 (0.6) 2 (0.7) 0 1 (3.7)
Nausea 13 (1.5) 4 (0.6) 2 (0.4) 1 (0.3) 0 0
ALT increased 8 (0.9) 6 (0.9) 1 (0.2) 0 0 0
AST increased 9 (1.0) 3 (0.4) 0 1 (0.3) 1 (0.8) 0
Diarrhea 9 (1.0) 3 (0.4) 0 3 (1.0) 0 0
Rash† 9 (1.0) 3 (0.4) 1 (0.2) 0 0 0
Stomatitis† 8 (0.9) 4 (0.6) 3 (0.6) 1 (0.3) 0 0
Anemia† 9 (1.0) 3 (0.4) 2 (0.4) 4 (1.4) 2 (1.7) 0
Vomiting 8 (0.9) 3 (0.4) 2 (0.4) 1 (0.3) 0 0
Pyrexia 8 (0.9) 2 (0.3) 1 (0.2) 1 (0.3) 0 0
Permanent discontinuations§
Any AE 37 (4.2) 20 (3.0) 8 (1.6) 3 (1.0) 3 (2.5) 1 (3.7)
Neutropenia† 6 (0.7) 4 (0.6) 1 (0.2) 1 (0.3) 1 (0.8) 0
ALT increased 3 (0.3) 1 (0.1) 0 0 0 0
Infections† 2 (0.2) 2 (0.3) 0 0 0 0
Fatigue 2 (0.2) 1 (0.1) 1 (0.2) 0 1 (0.8) 1 (3.7)
Disease progression 2 (0.2) 0 1 (0.2) 0 0 0
*AEs associated with dose reductions in 1% or more of patients during the first three years of palbociclib treatment are shown. AE ¼ adverse event; ALT ¼ alanine ami-
notransferase; AST ¼ aspartate aminotransferase.
†Cluster terms were used and are defined in the Supplementary Appendix (available online).
‡AEs associated with temporary treatment discontinuations in 1% or more of patients during the first three years of palbociclib treatment are shown. A temporary
dose discontinuation included any interruption and resumption of treatment within the same cycle or at the start of a new cycle (ie, cycle delays).
§AEs associated with permanent discontinuation in more than two palbociclib-treated patients during the first three years of treatment are shown.
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Figure 4. Dose reductions (A), dose interruptions (B), and granulocyte colony-stimulating factor (G-CSF) therapy (C) by cycle. Patients could have had a dose reduction
and/or dose interruption in more than one cycle. Patients with one or more dose reductions or one or more dose interruptions in a cycle are only reported once in the
respective cycle. Patients with one or more G-CSF medications (including filgrastim, pegfilgrastim, lenograstim, and/or G-CSF) concomitant in the respective cycle are
reported. Percentages were computed as n/N*100. n ¼ number of patients with at least one dose reduction or dose interruption per dosing records in the respective cy-
cle; N ¼ number of patients taking palbociclib during the cycle.
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worth noting, however, that QoL can be maintained in patients
treated with palbociclib plus endocrine therapy (23,24) through
the use of appropriate supportive care and dose modifications
as needed to manage AEs such as neutropenia, the most com-
mon AE associated with palbociclib (3).
Another therapeutic strategy to enhance the efficacy of en-
docrine therapies in patients with HRþ/HER2- advanced breast
cancer involves combining the mechanistic target of rapamycin
(mTOR) pathway inhibitor everolimus with exemestane (25).
BOLERO-2 clinical trial reports, which showed the effects of
everolimus plus exemestane in patients with HRþ breast cancer
who had relapsed on nonsteroidal aromatase inhibitors (26),
indicate that toxicities tended to occur early after treatment ini-
tiation and necessitated dose reduction(s) and more discontinu-
ations than the placebo plus exemestane arm, although the AE
incidence with everolimus decreased over time (25), as was ob-
served in this analysis with palbociclib plus endocrine therapy.
In the BOLERO-2 study, the most common any grade AEs,
reported for 15.0% or more of the 238 patients who received the
less intensive regimen of endocrine therapy (exemestane) plus
placebo after a median of 12 weeks’ exposure, were nausea
(27%), fatigue (26%), diarrhea (16%), and arthralgia (16%) (26). In
the endocrine monotherapy arm of this pooled safety study,
those same AEs (any grade) were reported in 25%, 27%, 18%, and
25% of patients, respectively, demonstrating that AEs associated
with endocrine therapy alone are consistently less toxic and
that their safety profile is not altered over time for up to three
years.
Currently, most of the safety data pertaining to CDK4/6
inhibitors received concomitantly during endocrine-based ther-
apy for HRþ/HER2- advanced breast cancer in women represent
an evaluation after a relatively short follow-up period. The lon-
gest safety follow-up of any CDK4/6 inhibitor in the breast can-
cer setting is five years for palbociclib plus letrozole in the
PALOMA-1 study (December 30, 2016, data cutoff), reported in
conjunction with overall survival (12). Although these data were
used to assess cumulative incidence annually over five consec-
utive years to reveal no new safety concerns, as a single study,
it included only 83 patients, and, although informative, it must
be viewed in that context. This pooled analysis assesses AEs
reported for 872 patients treated with palbociclib plus endocrine
therapy across three phase III clinical trials after a follow-up of
up to 50 months and represents the most comprehensive safety
report of CDK4/6 inhibitor use for advanced breast cancer at this
time.
Some limitations may exist with respect to the generalizabil-
ity of these safety findings. The representation of blacks in this
pooled analysis was 2.5% or less of the study population in ei-
ther arm; Asian patients constituted 16.6% and 13.6% of the
women in the palbociclib-treated and endocrine therapy only
arms, respectively. Additionally, patients with certain comor-
bidities or those taking certain concomitant medications were
excluded from taking part in the clinical trials that formed the
basis of our analyses; thus, the findings of our analyses may not
be applicable to those patients who were excluded from these
trials.
Based on these long-term safety analyses, there is no evi-
dence of specific cumulative or delayed toxicities resulting
from prolonged treatment with palbociclib combined with en-
docrine therapy for HRþ/HER2- ABC, supporting the use of pal-
bociclib plus endocrine therapy in the ongoing investigation of
their utility in early breast cancer as adjuvant treatments
(NCT02513394).
Funding
These analyses, and the studies included in these analyses,
were sponsored by Pfizer Inc.
Notes
Affiliations of authors: Institut Curie, Paris, France (VD);
University of California San Francisco Helen Diller Family
Comprehensive Cancer Center, San Francisco, CA (HSR); Pfizer
Inc, Collegeville, PA (PS, CHB); British Columbia Cancer Agency,
Vancouver, BC, Canada (KG); Robert H. Lurie Comprehensive
Cancer Center, Feinberg School of Medicine, Chicago, IL (MC);
Peter MacCallum Cancer Centre, University of Melbourne,
Melbourne, VIC, Australia (SL); Istituto Europeo di Oncologia,
Milan, Italy (MC); Pfizer Inc, La Jolla, CA (DRL); Pfizer Inc, Milano,
Italy (AM); Pfizer Inc, San Francisco, CA (EG); David Geffen
School of Medicine, Los Angeles, CA (DJS, RSF); Institute of
Cancer Research and Royal Marsden Hospital, London, UK
(NCT).
Pfizer Inc funded the study designs, conduct, data collection,
and data analysis. All authors were responsible for data inter-
pretation, writing or revising the manuscript for intellectual
content, and the decision to submit the manuscript for publica-
tion. The authors have no conflicts of interest.
We thank the patients, investigators, and study personnel
who participated in the PALOMA trials. PALOMA studies 1, 2,
and 3 (NCT00721409, NCT01740427, NCT01942135, respectively)
were sponsored by Pfizer. Editorial support was provided by
Susan Reinwald, PhD, and Johna Van Stelten, PhD, both of
Complete Healthcare Communications, LLC (West Chester, PA),
a CHC Group Company, and was funded by Pfizer.
References
1. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor pal-
bociclib in combination with letrozole versus letrozole alone as first-line
treatment of oestrogen receptor-positive, HER2-negative, advanced breast
cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 2015;
16(1):25–35.
2. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib
versus fulvestrant plus placebo for treatment of hormone-receptor-positive,
HER2-negative metastatic breast cancer that progressed on previous endo-
crine therapy (PALOMA-3): Final analysis of the multicentre, double-blind,
phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439.
3. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast
cancer. N Engl J Med. 2016;375(20):1925–1936.
4. Turner NC, Huang Bartlett C, Cristofanilli M. Palbociclib in hormone-
receptor-positive advanced breast cancer. N Engl J Med. 2015;373(17):
1672–1673.
5. O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibi-
tors. Nat Rev Clin Oncol. 2016;13(7):417–430.
6. Boer K. Impact of palbociclib combinations on treatment of advanced estro-
gen receptor-positive/human epidermal growth factor 2-negative breast can-
cer. OncoTargets Ther. 2016;9:6119–6125.
7. Finn R, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6
inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-
positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):
1–13.
8. Thanarajasingam G, Atherton PJ, Novotny PJ, Loprinzi CL, Sloan JA, Grothey
A. Longitudinal adverse event assessment in oncology clinical trials: The
Toxicity Over Time (ToxT) analysis of Alliance trials NCCTG N9741 and
979254. Lancet Oncol. 2016;17(5):663–670.
9. Study of letrozole with or without palbociclib (PD-0332991) for the first-line
treatment of hormone-receptor positive advanced breast cancer
(NCT00721409). https://clinicaltrials.gov/ct2/show/NCT00721409?term¼NCT
00721409&rank¼1. Accessed July 12, 2017.
10. A study of palbociclib (PD-0332991) þ letrozole vs. letrozole for 1st Line
treatment of postmenopausal women with ERþ/HER2- advanced breast
cancer (PALOMA-2) (NCT01740427). https://clinicaltrials.gov/ct2/show/
NCT01740427?term¼NCT01740427&rank¼1. Accessed July 12, 2017.
A
R
T
IC
LE
V. Dieras et al. | 429
11. Palbociclib (PD-0332991) combined with fulvestrant in hormone receptorþ
HER2-negative metastatic breast cancer after endocrine failure (PALOMA-3)
(NCT01942135). https://clinicaltrials.gov/ct2/show/NCT01942135?term¼NCT
01942135&rank¼1. Accessed July 12, 2017.
12. Finn RS, Crown J, Lang I, et al. Overall survival results from the randomized
phase 2 study of palbociclib in combination with letrozole vs letrozole alone
for first-line treatment of ERþ/HER2– advanced breast cancer (PALOMA-1;
TRIO-18). J Clin Oncol. 2017;35.
13. Temple R. Hy’s law: Predicting serious hepatotoxicity. Pharmacoepidemiol Drug
Saf. 2006;15(4):241–243.
14. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy
for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748.
15. Durairaj C, Ruiz-Garcia A, Gauthier ER, et al. Palbociclib has no clinically rele-
vant effect on the QTc interval in patients with advanced breast cancer.
Anticancer Drugs. 2018;29(3):271–280.
16. Verma S, Huang Bartlett C, Schnell P, et al. Palbociclib in combination with
fulvestrant in women with hormone receptor-positive/HER2-negative ad-
vanced metastatic breast cancer: Detailed safety analysis from a multicenter,
randomized, placebo-controlled, phase III study (PALOMA-3). Oncologist.
2016;21(10):1165–1175.
17. Dieras V, Harbeck N, Joy AA, et al. PALOMA-2: Neutropenia patterns in
patients with estrogen receptorpositive/human epidermal growth factor
receptor 2negative first-line advanced breast cancer receiving palbociclib
plus letrozole. Paper presented at: 42nd Congress of the European Society for
Medical Oncology; September 8–12, 2017; Madrid, Spain.
18. Zheng J, Yu Y, Durairaj C, et al. Palbociclib exposure-response analyses in the
treatment of hormone-receptor positive (HRþ), human epidermal growth
factor receptor 2 negative (HER2–) advanced breast cancer (ABC). Paper
presented at: 40th Annual San Antonio Breast Cancer Symposium; December
5–9, 2017; San Antonio, TX.
19. Sun W, Yu Y, Hoffman J, Turner NC, Cristofanilli M, Wang D. Palbociclib
exposure-response analyses in second-line treatment of hormone recep-
torpositive advanced breast cancer. Paper presented at: American Society
of Clinical Oncology Annual Meeting; June 2–6, 2017; Chicago, IL.
20. Hu W, Sung T, Jessen B, et al. Mechanistic investigation of bone marrow sup-
pression associated with palbociclib and its differentiation from cytotoxic
chemotherapies. Clin Cancer Res. 2016;22(8):2000–2008.
21. IBRANCE (Palbociclib). Summary of Product Characteristics. Kent, UK: Pfizer
Limited; 2018.
22. Ibrance (Palbociclib). Full Prescribing Information. New York: Pfizer; 2018.
23. Rugo H, Dieras V, Gelmon K, et al. Impact of palbociclib plus letrozole on
health-related quality of life compared with letrozole alone in treatment-naive
postmenopausal patients with ERþHER2 advanced/metastatic breast cancer:
Results from PALOMA-2. Paper presented at: 41st Congress of the European
Society for Medical Oncology; October 7–11, 2016; Copenhagen, Denmark.
24. Harbeck N, Iyer S, Turner N, et al. Quality of life with palbociclib plus fulves-
trant in previously treated hormone receptor-positive, HER2-negative meta-
static breast cancer: Patient-reported outcomes from the PALOMA-3 trial.
Ann Oncol. 2016;27(6):1047–1054.
25. Rugo HS, Pritchard KI, Gnant M, et al. Incidence and time course of
everolimus-related adverse events in postmenopausal women with hor-
mone receptor-positive advanced breast cancer: Insights from BOLERO-2.
Ann Oncol. 2014;25(4):808–815.
26. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal
hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):
520–529.
A
R
T
IC
LE
430 | JNCI J Natl Cancer Inst, 2018, Vol. 111, No. 4
